Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Gains from Investment Securities: 2019-2024

Historic Gains from Investment Securities for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Dec 2024 value amounting to -$2.0 million.

  • Maravai Lifesciences Holdings' Gains from Investment Securities fell 67.00% to -$334,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.2 million, marking a year-over-year decrease of 523.47%. This contributed to the annual value of -$2.0 million for FY2024, which is 106.10% down from last year.
  • Maravai Lifesciences Holdings' Gains from Investment Securities amounted to -$2.0 million in FY2024, which was down 106.10% from $32.9 million recorded in FY2023.
  • Maravai Lifesciences Holdings' 5-year Gains from Investment Securities high stood at $32.9 million for FY2023, and its period low was -$2.4 million during FY2020.
  • Moreover, its 3-year median value for Gains from Investment Securities was $23.0 million (2022), whereas its average is $18.0 million.
  • In the last 5 years, Maravai Lifesciences Holdings' Gains from Investment Securities tumbled by 251.60% in 2020 and then skyrocketed by 1,029.02% in 2021.
  • Maravai Lifesciences Holdings' Gains from Investment Securities (Yearly) stood at -$2.4 million in 2020, then soared by 1,029.02% to $22.5 million in 2021, then grew by 2.49% to $23.0 million in 2022, then skyrocketed by 42.68% to $32.9 million in 2023, then slumped by 106.10% to -$2.0 million in 2024.